FI54124C - Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat - Google Patents

Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat

Info

Publication number
FI54124C
FI54124C FI27/73A FI2773A FI54124C FI 54124 C FI54124 C FI 54124C FI 27/73 A FI27/73 A FI 27/73A FI 2773 A FI2773 A FI 2773A FI 54124 C FI54124 C FI 54124C
Authority
FI
Finland
Prior art keywords
therapeutic
dihydropyrrolo
carbonyloxy
piperazinyl
oxo
Prior art date
Application number
FI27/73A
Other languages
English (en)
Finnish (fi)
Other versions
FI54124B (fi
Inventor
Claude Cotrel
Claude Jeanmart
Mayer Naoum Messer
Original Assignee
Rhone Poulenc Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7200505A external-priority patent/FR2166314A1/fr
Priority claimed from FR7239731A external-priority patent/FR2205318A2/fr
Application filed by Rhone Poulenc Sa filed Critical Rhone Poulenc Sa
Publication of FI54124B publication Critical patent/FI54124B/fi
Application granted granted Critical
Publication of FI54124C publication Critical patent/FI54124C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI27/73A 1972-01-07 1973-01-05 Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat FI54124C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7200505A FR2166314A1 (en) 1972-01-07 1972-01-07 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls
FR7239731A FR2205318A2 (en) 1972-11-09 1972-11-09 6-substd 5-(4-methyl 1-piperazinyl)carbonyloxy 7-oxo - 5,6-dihydro-pyrrolo (3,4-b)pyrazines - tranquillizers and anticonvuls

Publications (2)

Publication Number Publication Date
FI54124B FI54124B (fi) 1978-06-30
FI54124C true FI54124C (fi) 1978-10-10

Family

ID=26216824

Family Applications (1)

Application Number Title Priority Date Filing Date
FI27/73A FI54124C (fi) 1972-01-07 1973-01-05 Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat

Country Status (22)

Country Link
US (1) US3862149A (cs)
JP (3) JPS523952B2 (cs)
AR (1) AR195097A1 (cs)
AT (1) AT323181B (cs)
AU (1) AU466586B2 (cs)
BE (1) BE793730A (cs)
CA (1) CA991183A (cs)
CY (1) CY915A (cs)
DD (1) DD102698A5 (cs)
DE (1) DE2300491C3 (cs)
DK (1) DK139359B (cs)
FI (1) FI54124C (cs)
GB (1) GB1358680A (cs)
HK (1) HK60077A (cs)
HU (1) HU164821B (cs)
IE (1) IE37056B1 (cs)
IL (1) IL41232A (cs)
LU (1) LU66800A1 (cs)
NL (1) NL7217852A (cs)
NO (1) NO136843C (cs)
OA (1) OA04285A (cs)
SE (1) SE398503B (cs)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2322601A1 (fr) * 1975-09-04 1977-04-01 Rhone Poulenc Ind Nouveaux derives de l'isoindoline, leur preparation et les compositions qui les contiennent
AR208414A1 (es) * 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
EP0091241B1 (en) * 1982-04-02 1988-12-28 Takeda Chemical Industries, Ltd. Condensed pyrrolinone derivatives, and their production
JPS6169773A (ja) * 1984-09-14 1986-04-10 Takeda Chem Ind Ltd イソインドリノン誘導体
JPS6297400U (cs) * 1985-12-09 1987-06-20
FR2607504B1 (fr) * 1986-12-02 1989-01-27 Rhone Poulenc Sante Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2671800B1 (fr) * 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
AU3245593A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
AU3275993A (en) * 1991-12-02 1993-06-28 Sepracor, Inc. Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
CN1206996C (zh) 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
US6339086B1 (en) * 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
ES2203319B1 (es) * 2002-04-03 2005-03-01 Universidad De Oviedo Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
JP5646126B2 (ja) 2003-12-11 2014-12-24 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 鎮静剤と神経伝達物質調節剤の併用、および睡眠の質の向上方法および鬱の治療方法
CA2614282A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7476737B2 (en) * 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
WO2007088073A1 (en) * 2006-02-03 2007-08-09 Synthon B.V. Zopiclone resolution using l-tartaric acid
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2643199A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007109799A2 (en) * 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
JP2008543953A (ja) * 2006-04-20 2008-12-04 テバ ファーマシューティカル インダストリーズ リミティド エスゾピクロン結晶形態ａ、実質的に純粋なエスゾピクロン及び光学的に豊富なエスゾピクロンを調製するための方法
CN101058581B (zh) * 2006-04-21 2011-06-08 天津天士力集团有限公司 右佐匹克隆中间体6-(5-氯-2-吡啶基)-5,7-二氧代-6,7-二氢-5H-吡咯并[3,4-b]吡嗪的制备方法
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
JP2009536667A (ja) * 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
WO2008002629A1 (en) * 2006-06-26 2008-01-03 Teva Pharmaceutical Industries Ltd. Process for the preparation of zopiclone
AU2007292848A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US7786304B2 (en) * 2006-11-06 2010-08-31 Centaur Pharmaceutical Pvt. Ltd. Process for the preparation of eszopiclone
TW200846340A (en) * 2007-01-31 2008-12-01 Teva Pharma Methods for preparing eszopiclone
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
TW200918534A (en) * 2007-06-25 2009-05-01 Teva Pharma Racemization process of R-zopiclone
EP2020403A1 (en) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
US20090198058A1 (en) * 2007-08-06 2009-08-06 Dhananjay Govind Sathe Process for Preparation of Dextrorotatory Isomer of 6-(5- chloro-pyrid-2-yl)-5-[(4-methyl -1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine (Eszopiclone)
AU2008346110A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd. Crystalline polymorphic forms of zopiclone, processes for their preparation and their pharmaceutical compositions
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CN100467471C (zh) * 2007-12-19 2009-03-11 齐鲁天和惠世制药有限公司 佐匹克隆的制备方法
CA2747000C (en) * 2007-12-19 2013-09-03 Sunovion Pharmaceuticals Inc. Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20110053945A1 (en) * 2007-12-19 2011-03-03 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2010088385A1 (en) 2009-01-30 2010-08-05 Sepracor Inc. Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5h-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN105399745A (zh) * 2015-12-17 2016-03-16 天津华津制药有限公司 一种吡嗪并羟基吡咯烷酮类化合物的制备方法
WO2017214442A1 (en) 2016-06-08 2017-12-14 President And Fellows Of Harvard College Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome
CN106220630B (zh) * 2016-07-23 2019-12-10 迪嘉药业集团有限公司 一种n-取代吡咯并[3,4-b]吡嗪-5,7(6h)-二酮的制备方法
WO2019226808A1 (en) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
AU2019279858A1 (en) 2018-05-29 2020-11-26 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
EP3946390A4 (en) 2019-03-25 2022-12-21 President and Fellows of Harvard College COMPOSITIONS AND METHODS TO REDUCE TACTILE DYSFUNCTION, ANXIETY AND SOCIAL DISABILITIES
CN114437027A (zh) * 2021-12-22 2022-05-06 深圳市祥根生物医药有限公司 一种佐匹克隆n-氧化杂质的制备方法

Also Published As

Publication number Publication date
IE37056L (en) 1973-07-07
DE2300491A1 (de) 1973-07-19
LU66800A1 (cs) 1973-07-18
AR195097A1 (es) 1973-09-10
AU466586B2 (en) 1975-10-30
CA991183A (fr) 1976-06-15
NO136843C (no) 1977-11-16
JPS5248688A (en) 1977-04-18
DK139359C (cs) 1979-07-09
JPS5231358B2 (cs) 1977-08-13
DD102698A5 (cs) 1973-12-20
JPS4876892A (cs) 1973-10-16
IE37056B1 (en) 1977-04-27
US3862149A (en) 1975-01-21
DE2300491C3 (de) 1978-05-18
DK139359B (da) 1979-02-05
CY915A (en) 1977-12-23
DE2300491B2 (de) 1977-09-08
GB1358680A (en) 1974-07-03
JPS5248687A (en) 1977-04-18
IL41232A0 (en) 1973-03-30
HU164821B (cs) 1974-04-11
NO136843B (no) 1977-08-08
SE398503B (sv) 1977-12-27
FI54124B (fi) 1978-06-30
BE793730A (fr) 1973-07-05
OA04285A (fr) 1979-12-31
JPS535315B2 (cs) 1978-02-25
AU5075473A (en) 1974-07-04
HK60077A (en) 1977-12-09
NL7217852A (cs) 1973-07-10
IL41232A (en) 1975-12-31
JPS523952B2 (cs) 1977-01-31
AT323181B (de) 1975-06-25

Similar Documents

Publication Publication Date Title
FI54124C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-(4-metyl-1-piperazinyl)-karbonyloxi-7-oxo-5,6-dihydropyrrolo(3,4-b)pyrazinderivat
SE402592B (sv) Forfarande for framstellning av 2-alkyl-3-acyl-pyrazolo(1,5-a)pyridiner
NO144885C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive benzodiazepinderivater
SE432767B (sv) Forfarande for framstellning av oxazolo-(5,4-b)-pyridiner
NO138566C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,1,3-benzotiadiazol-derivater
NO145056C (no) (s)-1-aryloksy-2-propanolderivater for fremstilling av terapeutisk aktive (s)-1-aryloksy-3-amino-2-propanolderivater
SE419990B (sv) Analogiforfarande for framstellning av s-triazolo(4,3-b)pyridaziner
SE381047B (sv) Forfarande for framstellning av 3-substituerade 1,2-bensisoxazolderivat
SE399879B (sv) Kemiska mellanprodukter till anvendning for framstellning av terapeutiskt verdefulla 1,2,3,4-tetrahydro-4-fenyl-isokinolinderivat
FI54312B (fi) Foerfarande foer framstaellning av tieno-(2,3-d)pyrimidinderivat med avsoendring av urinsyra i urin utoekande
NO137966C (no) Analogifremgangsmaate til fremstilling av antibakterielt virksomme 5-oksopyrido-(2,3-d)-pyrimidinderivater
NO141850C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive pyrazolderivater.
SE402012B (sv) Analogiforfarande for framstellning av s-triazolo(1,5-a)(1,4)diazepinderivat
SE412234B (sv) Analogiforfarande for framstellning av s-triazolo(1,5-a)pyridinderivat
SE410604B (sv) Analogiforfarande for framstellning av pyrazolo(3,4-e)(1,4)diazepinforeningar
FI55660B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara pyrazolo(3,4-b)pyridinderivat
CA988931A (en) Sulfur derivatives of pyrazolo(3,4-b)pyridines
SE397827B (sv) Forfarande for framstellning av 1-aminometyl-2,2-difenylcyklopropankarboxamidderivat med terapeutisk verkan
FI54712B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 5-((4-metylpiperazin-1-yl)karbonyloxi)-7-oxo-2,3,6,7-tetrahydroditiino (1,4)(2,3-c)pyrroler
SE380804B (sv) Anologiforfarande for framstellning av s-triazolo (1,5-a) (1,4)
FI56386B (fi) Foerfarande foer framstaellning av oktahydro-oxazolo 3,2-a pyrrolo 2,1-c pyrazin-derivat
SE397832B (sv) Analogiforfarande for framstellning av s-triazolo(4,3-a)(1,4)bensodiazepinderivat
SE382983B (sv) Analogiforfarande for framstellning av oxazolo(3,2-d) (1,4) bensodiazepinderivat
SE408302B (sv) Forfarande for framstellning av 1,4-bensodiazepin-derivat
SE381046B (sv) Forfarande for framstellning av 1,4-bensodiazepinderivat